? They issue convertible notes when cash is needed. That is the way pre-revenue biopharma's works. They get whatever they need on demand pretty much. Its these notes that create money/value for investors, who can catch stocks like RDGL under .01 as the noteholder drops off their load. Often the company is very much undervalued when a noteholder sells, which is the opportunity in pinky land. Usually noteholders hire market makers to artificially drop the price so they can convert as well. RDGL never should have gone to .0027. All forced.
These guys are planning to deploy Isopet at any moment. All it takes is 1 clinic to jump on its gangbusters from there.
News 
Market Data 
Discover 
AI
